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  1Abstract 
 
We describe a method for the determination of the two major urinary metabolites of 
vitamin K as the methyl esters of their agyclone structures, 2-methyl-3-(3΄-3΄-
carboxymethylpropyl)-1,4-naphthoquinone (5C-side-chain metabolite) and 2-methyl-
3-(5΄-carboxy-3΄-methyl-2΄-pentenyl)-1,4-naphthoquinone (7C-side-chain 
metabolite), by HPLC with electrochemical detection (ECD) in the redox mode.   
Urinary salts were removed by reversed-phase (C18) solid phase extraction (SPE) and 
the predominately conjugated vitamin K metabolites hydrolysed with methanolic HCl.  
The resultant carboxylic acid aglycones were quantitatively methylated with 
diazomethane and fractionated by normal-phase (silica) SPE.  Final analysis was by 
reversed-phase (C18) HPLC with a methanol-aqueous mobile phase.  Metabolites were 
detected by amperometric, oxidative ECD of their quinol forms, which were 
generated by post-column coulometric reduction at an upstream electrode.  The assay 
gave excellent linearity (r
2 typically ≥ 0.999) and high sensitivity with an on-column 
detection limit of <3.5 fmol (<1pg).  The inter-assay precision was typically 10%.  
Metabolite recovery was compared to that of an internal standard (2-methyl-3-(7-
carboxy-heptyl)-1,4-naphthoquinone), added to urine samples just before analysis.   
Using this methodology we confirmed that the 5C- and 7C-metabolite were major 
catabolites of both phylloquinone (vitamin K1) and menaquinones (vitamin K2) in 
humans.  We propose that the measurement of urinary vitamin K metabolite excretion 
is a candidate non-invasive marker of total vitamin K status.  
 
Supplementary key words vitamin K, phylloquinone, menaquinones, urinary 
vitamin K metabolites, aglycones, HPLC-ECD 
 
  2INTRODUCTION 
Compounds with vitamin K activity have a common 2-methyl-1, 4-
naphthoquinone nucleus and a variable alkyl substituent at the 3 position.  The major 
naturally occurring K vitamins are the plant form phylloquinone (vitamin K1) and 
multiple forms of menaquinones (vitamins K2), predominately of bacterial origin.   
Phylloquinone (abbreviated K1) has a 20-carbon, phytyl side chain whereas 
menaquinones have multi-prenyl side chains, their number being indicated by a suffix 
(i.e. menaquinone-n, abbreviated MK-n).  In a typical Western diet, K1 and MK-n 
account for about 90% and 10% of vitamin K intakes respectively (1).  Dietary MK-n 
mainly comprise MK-4, MK-7, MK-8, and MK-9 (2), although MKs with longer side 
chains up to MK-13 are present in human liver (3,4). Menadione (abbreviated K3) is a 
synthetic vitamin K homologue that lacks the side chain at the 3-position and which, 
despite toxicity issues and restricted biological activity, is still available in some 
countries as a pharmaceutical vitamin K preparation in the form of menadiol sodium 
phosphate (5) or similar water-soluble salt.  The biological activity of K3  in vivo 
depends entirely on its prenylation to MK-4 (6,7).  
At the cellular level the cofactor role of vitamin K for the post-translational 
conversion of specific peptide-bound glutamate (Glu) to -carboxyglutamate (Gla) is 
well established as is the intimately associated metabolic cycle whereby the vitamin K 
2,3 epoxide metabolite generated during -glutamyl carboxylation is salvaged (8) (9). 
Other aspects of the intermediary metabolism of vitamin K, including the 
processes leading to vitamin K catabolism and excretion, are much less understood.  
During the 1970’s human studies employing radio-labelled-tracer and unlabelled 
pharmacological doses showed that K1 was rapidly and extensively catabolised via the 
urine and bile (10) (11) (12).  These studies established that the major aglycone 
  3metabolites of K1 were two side-chain shortened carboxylic acids with the structures 
2-methyl-3-(3-3-carboxymethylpropyl)-1,4-naphthoquinone (side chain length 5 
carbon atoms, structure IV in Fig. 1) and 2-methyl-3-(5-carboxy-3-methyl-2-
pentenyl)-1,4-naphthoquinone (side chain length 7 carbon atoms, structure III in Fig. 
1) respectively. (10) (11) (12).  Both 5C- and 7C-aglycones were excreted as water-
soluble conjugates, mainly with glucuronic acid.   
At the time of isolation and characterization of these two metabolites 
(henceforward abbreviated to 5C- and 7C-aglycones respectively), the role of vitamin 
K was thought to be limited to its classical coagulation function, and human 
deficiency at the population level was only considered a problem during the first 6-
months of life (13).  However the subsequent discovery of many more vitamin K-
dependent proteins (also called Gla proteins), with a widespread tissue distribution, 
has lead to a re-evaluation of the general physiological function and health roles of 
vitamin K.  Putative roles of Gla proteins now extend to a diversity of functions such 
as the regulation of bone turnover and calcification (14) (15), inhibition of vascular 
calcification (16), and roles in vascular repair processes (17), cell cycle regulation, 
cell-cell adhesion, and signal transduction (18).  Of particular note is the accumulating 
body of evidence that has linked a suboptimal vitamin K reserves in bone to an 
increased risk of osteoporotic fracture (19) (20) or to reduced bone mineral density 
(21).  To address this issue, and other questions, there has been a need to develop new 
biochemical measures to monitor vitamin K status in human populations (22).   
Current measures include the direct measurement of circulating vitamin K (as an 
indicator of tissue stores) and functional assessments of the -carboxylation status of 
specific Gla proteins such as prothrombin and osteocalcin representing hepatic and 
bone -carboxylation capacity respectively.  In addition, measurements of urinary free 
  4Gla offer an overall assessment of the -carboxylation status of Gla proteins.  Each of 
these status assessments has a number of methodological and interpretational 
drawbacks (23) (24) (25).  Although useful in many situations, the measurement of 
circulating vitamin K to assess tissue stores has the major disadvantage that only K1 is 
commonly measured to the detriment of MKs.  MKs from the diet (1) (2) and possibly 
from intestinal synthesis (3) (4) may make a significant contribution to total daily 
vitamin K intake (1), and the liver stores of vitamin K are predominately long chain 
MKs (3) (4).  
Here we describe the development of chromatographic techniques to quantify 
the two major urinary aglycones of vitamin K with high sensitivity, enabling their 
measurement at low physiological concentrations.  We chose ECD in the redox mode 
for the final analytical HPLC stage as this method is especially suitable for quinone 
compounds and has been successfully used for the determination of vitamin K in 
serum (26) (27).  To find out whether the 5C- and 7C-aglycones are common to all K 
vitamins, we obtained urine samples from adults before and after supplementation 
with different doses of K1, MK-4, MK-7 and K3.  We also analysed urine samples 
from newborn infants who, as a group, are known to have precariously low vitamin K 
stores, and are routinely given vitamin K prophylaxis at birth.  
 
 
 
 
 
 
 
  5MATERIALS AND METHODS 
Reagents 
The 5C-aglycone (2-methyl-3-(3΄-3΄-carboxymethylpropyl)-1,4-
naphthoquinone), 7C-aglycone (2-methyl-3-(5΄-carboxy-3΄-methyl-2΄-pentenyl)-1,4-
naphthoquinone) and the compound (2-methyl-3-(7΄-carboxy-heptyl)-1,4-
naphthoquinone) used for the internal standard (IS), are not commercially available 
and were synthesised for this study (28).  The -lactone form of the 7C-aglycone (2-
methyl-3-(5-carboxy-3-hydroxy-3-methylpentyl)-1,4-naphthoquinone lactone), also 
known as vitamin K -lactone, was a gift to MJS from Hoffmann-La Roche and Co., 
Basle, Switzerland.  Organic solvents were of HPLC grade (Rathburns Chemicals, 
Walkerburn, Scotland).  Water for ECD was purified using a Purite Neptune water 
purification system (Jencons-PLS, Leighton Buzzard, UK).  Potassium hydroxide 
(Ultra grade), 1-methyl-3-nitro-1-nitrosoguanidine (MNNG), and 
ethylenediaminetetraacetic acid (disodium salt, dihydrate, Analar grade) were 
obtained from Sigma-Aldrich (Dorset, UK).  Anhydrous sodium acetate, glacial acetic 
acid, and 3M HCl, all AristaR grade, were obtained from BDH (Lutterworth, Leics, 
UK).  Nitrogen gas (oxygen free), for removal of solvents, was obtained from BOC 
(Guildford, Surrey, UK).    
Apparatus 
Solid phase extraction (SPE) procedures were performed using Isolute SPE 
C18 (100 mg, 1 ml reservoir) cartridges (Jones Chromatography, Mid Glamorgan, UK) 
and Sep-Pak™ silica plus cartridge (Waters Ltd, Elstree, Herts, UK) with a SPE 
vacuum manifold.  
For HPLC we used a Gynkotek model 480 pump with pulse damper, a 
Waters™ 717 plus Autosampler, and an in-line De-Jour, X-Act HPLC degassing unit.  
  6For on-line detection we used a DECADE electrochemical detector (Antec, Leyden, 
The Netherlands) equipped with an in-line cell (model 5011) containing dual porous 
graphite coulometric electrodes in series (ESA Analytical Limited, Aylesbury, Bucks, 
UK) and an amperometric, wall jet electrode situated immediately downstream (Antec 
model VT-03).  Chromatographic data was captured using a data chromatography 
manager (Waters). 
Urine collection and human subject protocols  
Twenty four-hour and spot urine collections were made into plastic containers. 
Owing to the photosensitive nature of the metabolites, the urine containers were 
protected from sources of strong light.  Urine collections were stored at room 
temperature for the duration of the collection period and aliquots frozen at -70C until 
analysis.  No significant metabolite loss occurred under these conditions.   
We investigated urinary 5C- and 7C-aglycone excretion in healthy adult 
volunteers.  Measurements were made in spot or 24-hour urine collections in both 
unsupplemented and vitamin K-supplemented subjects.  For the supplementation 
studies the subjects took different forms of vitamin K orally at doses previously used 
for the treatment or prevention of several pathologies.  The vitamin K compounds 
used were K1 (2 mg and 50 mg) (29); two homologues representative of the 
menaquinone series, namely MK-4 (45 mg) (30), and MK-7 (1 mg) (31); and K3 (20 
mg) (5).  The amounts of 5C- and 7C-aglycone excreted in the urine were measured 
pre- and post- supplementation. 
A number of spot urines were also collected from newborn infants (2 males, 1 
female) before and after intramuscular K1 prophylaxis with 1 mg Konakion Neonatal 
(Roche, Basel, Switzerland).   
  7All adult volunteers and guardians of newborns gave full written informed 
consent prior to participation in these investigations.  
Assay Procedure 
         A flowchart showing the extraction and analytical procedures is shown in Fig. 2.   
Extraction and hydrolysis of metabolites 
A C18 SPE cartridge was pre-washed with 1ml of methanol followed by 1 ml 
of deionised water.  Aliquots of 0.5 ml (unsupplemented subjects) or 0.05 ml (after 
vitamin K supplementation) of urine were loaded onto the SPE cartridge and allowed 
to elute to waste under gravity.  To remove urinary salts, the SPE cartridge was 
washed with 1 ml of deionised water at a flow rate of ~0.5 ml/min and the eluent 
discarded (32).  The conjugated vitamin K metabolites were then eluted into a clean 
tapered polypropylene test tube (12 ml capacity) with 2 ml of a methanolic stock 
solution containing 0.15 g of the IS and the eluent evaporated to dryness under a 
stream of N2 at 50C.  
Conjugated urinary vitamin K metabolites were hydrolysed overnight at room 
temperature (in the dark) with 1.1 ml of methanolic HCl (prepared by combining one 
volume of concentrated (35%) HCl with 4 volumes of methanol) (33).  The 
metabolites, now as their aglycones, were extracted into chloroform by the addition of 
1.1 ml chloroform and 1.0 ml water to the sample tube (34).  The upper methanolic-
aqueous layer was removed, and discarded.  To prevent acid-catalysed lactonisation of 
the 7C-aglycone during subsequent drying procedures, the lower chloroform layer 
was washed with 10 ml of deionised water to remove any residual mineral acid.  After 
brief shaking, and allowing the two phases to separate, the upper aqueous layer was 
discarded and the lower chloroform layer evaporated to dryness under a stream of N2 
at 50˚C. 
  8Methylation of aglycones  
The carboxylic acid forms of the vitamin K aglycones were converted to their methyl 
ester derivatives by reaction with freshly prepared ethereal diazomethane generated 
on a small scale by a modification of a method described elsewhere (35).  In brief, a 
mixture of 5M KOH (~20 ml) and diethyl ether (~15 ml) are placed into a small, 
screw capped bottle (100 ml-capacity Duran) and solid MNNG gradually added until 
sufficient diazomethane has been generated to turn the upper ether layer yellow 
(Caution: only perform in well-ventilated fume hood).  A volume of 0.5 ml of this 
ethereal diazomethane was then added to each urine extract.  Complete methylation of 
the carboxylic acid group of the aglycone-metabolites was achieved at room 
temperature within 5 minutes after which the diethyl ether was removed under a 
stream of N2 at 50C.  
Normal-phase SPE of methylated aglycones 
Further fractionation of the urine extract was achieved by normal phase-SPE 
using Sep-Pak™ cartridges.  Each cartridge was attached to a 10-ml glass syringe 
with a Luer end fitting and activated by drawing through 2 ml of n-hexane. Each 
extract, was dissolved in 2 ml of n-hexane, and then pipetted into the glass syringe 
attached to the activated cartridge.  The n-hexane was drawn through the cartridge and 
the eluent discarded.  A further volume of 8 mL of n-hexane was added to the sample 
tube, the washings drawn through the cartridge, and discarded as before.  The vitamin 
K metabolites and IS were then eluted from the cartridge with 10 ml of n-
hexane-diethyl ether (85:15, v/v), and collected into a fresh polypropylene, stoppered, 
tapered test tube.  The solvent was removed under a stream of nitrogen at 50 C.  
Reversed-phase HPLC-ECD  
  9The final separation of the methylated aglycones was achieved by reversed-
phase HPLC using a Thermo Hypersil-Keystone HyPURITY C18 column (3m 
particle size, dimensions 100 x 4.4 mm supplied by Hichrom, Reading, Berks, UK) 
and a mobile phase consisting of 60: 40 (v/v) methanol–0.05M sodium acetate buffer 
(pH 3.0 and containing 0.1% EDTA) (26).  The flow rate was 1.0 ml/min.  Effluent 
from the column passed through the coulometric dual-electrode cell in which the twin, 
porous-graphite, electrodes were set at a negative potential (–1.2 V), thereby reducing 
the urinary vitamin K quinone metabolites and IS to their quinol states.  The effluent 
then passed to the amperometric wall jet electrode set at +0.3 V which resulted in the 
re-oxidation of the quinol forms of metabolites and IS to their respective quinones.  
Chromatograms were generated by monitoring the current (nA) at the wall jet 
electrode.    
Quantification of 5C- and 7C-aglycone metabolites 
From methanolic stock solutions of the 5C- and 7C-aglycones and the IS 
(methyl ester forms) we prepared a series of standards containing all 3 analytes with 
spectrophotometrically determined (E mM = 18.9 at 248 nm) weight ratios of 5C-
aglycone/IS and 7C-aglycone/IS ranging from 0.003 to 0.121.  Each chromatographic 
run included the direct injection of 10 l of each calibration standard.  For routine 
analyses (i.e. for physiological urinary concentrations of metabolites) the SPE-
fractionated extracts were reconstituted in 40 l of methanol and a volume of 10 l 
injected onto the RP-HPLC system.  For the determination of the much higher levels 
after vitamin K supplementation, the extract was reconstituted in 100 l of methanol 
and 10 l injected.  Metabolite concentrations were quantified by the method of peak-
height ratios.  For each chromatogram generated, the peak heights of 5C- and 7C-
aglycones were expressed as a ratio to the IS peak.  A calibration plot of peak height 
  10ratios of the standards versus their weight ratios gave excellent linearity (r
2 typically ≥ 
0.999) and was used to calculate the equivalent weight ratios of aglycone/IS for each 
unknown.  Multiplication of this weight ratio by the amount of IS originally added 
gave the amounts of aglycones in the volume of urine processed.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  11RESULTS 
Optimisation of extraction and conjugate-hydrolysis procedures 
 
The initial SPE procedure using C18 cartridges was an effective strategy for 
desalting the urine and concentrating the urinary metabolites in their conjugated 
forms.  True recovery experiments at this C18 SPE stage were not possible because 
there is limited information on the chemical nature and variety of conjugated 
metabolites in vivo and appropriate standards are unavailable.  Nevertheless, recovery 
experiments using the synthetic 5C-aglycone, 7C-aglycone and IS showed that there 
was no significant loss of vitamin K moieties at this stage.  Recoveries were reduced 
if lower eluting volumes (<2ml) of methanol were used, or if the urine was acidified 
(with HCl) to promote protonisation of the carboxylic acid metabolites.  Trials with 
other SPE cartridge chemistries with side chain lengths <C18 also resulted in a 
reduced recovery.  Analyte recovery was found to vary inversely with the flow rates 
of both the first aqueous wash and second methanolic elution steps.  Omission of this 
initial SPE stage increased the baseline current in the final electrochemical RP-HPLC 
analytical stage resulting in a decrease in assay sensitivity. 
After the initial SPE stage, conjugated metabolites of vitamin K were 
hydrolysed with methanolic HCl.  At room temperature, hydrolysis of conjugated 
metabolites with methanolic HCl was complete within 16 hours.  After hydrolysis, the 
lipid-soluble aglycones and IS were efficiently extracted into chloroform after the 
addition of further volumes of chloroform and water to form a two-phase system as 
described for the final stage of the Bligh and Dyer total lipid extraction technique 
(34).  A second extraction of the methanolic digest with chloroform did not improve 
the recovery of aglycones.    
  12Methyl ester derivatisation of carboxylic acid aglycones 
There were two main reasons for adopting a pre-HPLC methylation procedure 
to quantitatively convert the aglycone carboxylic acids to their respective methyl 
esters.  Firstly, exposure to methanol during the chromatographic procedures resulted 
in some inadvertent methylation, which was enhanced by use of methanolic HCl to 
deconjugate the aglycones.  Secondly, the reduced polarity of these methylated 
derivatives improved their retention in our RP-HPLC separation system.   
SPE purification of methylated aglycones 
An additional SPE purification stage using silica cartridges was introduced to 
remove interfering compounds, which prevented baseline resolution of the 5C- and 
7C-aglycones in the final HPLC-ECD analytical stage.  Optimisation of the 
composition of the eluting solvent was carried out using a standard mixture containing 
known concentrations of the 5C-aglycone, 7C-aglycone and IS.  A diethyl ether 
concentration of 15% diethyl ether in n-hexane (v/v) was found to give quantitative 
recoveries of the methylated aglycones and the IS while producing good baseline 
resolution on HPLC-ECD.  Recovery of the vitamin K aglycones and IS after this and 
previous purification stages was consistently >90% for each analyte with no inter-
analyte bias.   
Optimisation of HPLC-ECD Conditions 
 
The hydrodynamic voltammograms of the 5C- and 7C-aglycone methyl esters 
together with the IS are shown in Fig. 3.  A voltage of –1.2 V was selected as the 
applied potential in the upstream flow-through coulometric twin electrodes for 
quantitative reduction of the quinone forms of metabolites and IS to their 
corresponding quinols (this was the maximum possible voltage to the electrodes of the 
ESA coulometric cell when controlled by the DECADE instrument).  In selecting 
  13+0.3 V as the applied potential for the down stream amperometric electrode (for the 
re-oxidation of the respective quinols), a minimal degree of assay sensitivity was 
sacrificed.  However this reduced interferences from co-extracted and co-
chromatographed substances and resulted in a reduced background current. 
The EC reduction of the quinone to the quinol moiety was temperature-
dependent.  Increasing the temperature in which the reductive EC cell was housed 
improved overall sensitivity of the assay and we routinely operated the EC cells in the 
temperature range of 37-42C.  The methanol component of the mobile phase and 
system temperature were adjusted until the retention times of the 5C-aglycone, 7C-
aglycone and IS at a flow rate of 1 ml/min were ca. 8, 12 and 32 minutes respectively.  
Both reductive and oxidative EC cells were found to be robust and foul free after 
prolonged use.  
Calibration, Sensitivity, and Precision of the HPLC – EC assay 
The injection of varying amounts of the 5C- and 7C-aglycones and the IS gave 
good peak shapes and a linear detector response within and beyond the mass range 
used for quantification of the aglycones.  Typical chromatograms of a calibration 
standard solution and urinary extracts from both unsupplemented and vitamin K-
supplemented subjects are shown in Fig. 4.  The ‘on column’ lower limit of detection 
of 5C- and 7C-aglycones (defined as 5 x baseline noise) was <3.5 fmol (<1 pg).  The 
intra- and inter-assay co-efficients of variation (CV) for 5C- and 7C-aglycone 
determination in urine from a healthy, non-supplemented volunteer is shown in Table 
1. 
Mineral acid catalysed lactonization of 7C-aglycone side chain 
The 7C-aglycone in its acid form differs from the 5C-aglycone in having a 
double bond at the - position relative to the carboxyl group of the side chain.   
  14Organic acids with this ,-unsaturated structure are unstable to mineral acids and 
undergo cyclization to a 5-membered -lactone ring structure.  As has been previously 
demonstrated in radioisotopic studies, the 7C-aglycone in its carboxylic acid form is 
readily converted to 2-methyl-3-(5-carboxy-3-hydroxy-3-methylpentyl)-1,4-
naphthoquinone lactone (vitamin K -lactone, structure V in Fig. 1) under aqueous 
acidic conditions such as when mineral acid is used to release the aglycones from 
their conjugated forms in urine (10) (11) (12).  To find out whether we could 
demonstrate -lactonization by HPLC, we subjected 0.5 ml aliquots of urine (urine 
collected from a volunteer who had ingested 50 mg of K1) to hydrolysis with 1ml of 
aqueous 3M HCl at 70C for 60 minutes.  After aqueous HCl hydrolysis the 
aglycones were extracted with chloroform and subjected to the usual assay procedure.  
Treatment with mineral acid completely abolished the peak that co-chromatographed 
with the 7C-aglycone standard and resulted instead in an extra peak that co-
chromatographed with authentic vitamin K -lactone (data not shown).  A peak of 
vitamin K -lactone was not found in urine samples after hydrolysis of the metabolite 
conjugates with methanolic HCl hydrolysis or enzyme preparations of -
glucuronidase (also containing sulfatase).  
Confirmation of chromatographic peak identification 
Identification of the 5C- and 7C-methyl ester aglycone chromatographic peaks 
isolated from urine was initially achieved by confirming that they had identical 
chromatographic and chemical properties to the authentic synthetic standards.  The 
chemical similarities between analytes and standards included their hydrodynamic 
voltammograms, their sensitivity to light and, for the 7C-aglycone, the lability 
towards mineral acid and conversion to a compound chromatographically 
indistinguishable from vitamin K -lactone.  Definitive confirmation of correct peak 
  15assignment was provided by in vivo studies that confirmed that the chromatographic 
measurements responded to supplementation with different forms of vitamin K.   
Typical concentrations (corrected for creatinine) of 5C- and 7C-aglycones in 
urine samples collected on two consecutive days from 5 healthy, fasting adults 
(subjects A-E) are shown in Table 2.  Table 2 also shows the increase in urinary 
concentrations of both aglycones in response to supplementation with K1, MK-4, MK-
7 and K3 in a dose-dependent manner.  These studies provided confirmation of the 
chromatographic peak identity for the respective aglycones.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  16DISCUSSION 
As far as we are aware this is the first method to have been developed for the 
routine measurement of the two major urinary aglycones of vitamin K.  The method is 
sensitive requiring small sample volumes and the inter-assay precision was about 10% 
for both 5C- and 7C-aglycones.  Although we used the same principle of redox mode 
electrochemical detection as for a previous assay of the parent K vitamins (27) (36) 
the metabolite assay has proved to be much less susceptible to periodic loss of 
sensitivity.  In the serum vitamin K assay, this often-rapid loss of sensitivity is 
thought to be due to passivation of the electrodes by adsorbed species of vitamin K 
and co-extracted non-polar lipids (27) (36).  The lack of significant electrode 
passivation in the present assay may be related to the greater polarity of the 
metabolites and co-extracted urinary components, which makes them less likely to 
adsorb to the carbon electrodes than the highly lipophilic vitamin K and other lipids 
present in serum extracts.   
The 5C- and 7C- aglycones measured in this assay were derived by the 
chemical hydrolysis of conjugates by methanolic HCl.  This method of hydrolysis was 
previously employed for the isolation of the urinary aglycones of ubiquinone-7 (33) 
and phylloquinone (37) from rabbit urine.  Previous work from our laboratory has 
suggested that the majority of the 5C- and 7C-metabolites in human urine are excreted 
as glucuronides (10) (11).  We also confirmed in this study (data not shown) that 
incubation of urine with -glucuronidase released the same two 5C- and 7C-aglycones 
and gave identical chromatograms to those after methanolic HCl hydrolysis.  This 
does not exclude the possibility of other conjugates being present since 2-methyl-1, 4-
naphthoquinone (menadione, vitamin K3), which lacks the side chain, has been shown 
to be excreted as both glucuronide and the sulfate conjugates of the quinol form in rats 
  17(38) (39) and rabbits (40).  For routine quantitative analyses we chose methanolic HCl 
over enzymic hydrolysis for reasons of its greater convenience and efficiency, and to 
ensure complete hydrolysis of all conjugates present.   
The results in Table 2 show that in both unsupplemented and supplemented 
adults, the excretion of the 5C-aglycone is greater than the excretion of the 7C-
aglycone.  This is in agreement with early radioisotopic measurements of these two 
aglycones after the administration of tritium-labelled phylloquinone to adults (10) 
(11).  In the latter studies, the intravenous administration of single doses of 45-1000 
g of labelled phylloquinone resulted in a gradually increasing proportion of the 7C-
aglycone (assayed as vitamin K -lactone after acid hydrolysis) from an initial 13% to 
some 30-40% in successive urine collections made over the first 24 hours (10).  In 
rabbits, the administration of a huge (91 mg) intravenous dose of phylloquinone 
changed the percentage proportion of 7C-aglycone (in 24-hour urine collections) from 
13% in control animals to 57% post-supplementation (37).  This data suggests that 
whereas physiological amounts of phylloquinone are largely metabolised to the 
terminal 5C-aglycone, vitamin K supplementation may lead to a greater urinary 
excretion of the less extensively metabolised 7C-aglycone.  Interestingly, one of the 
infants studied here (Infant A, Table 2) excreted predominately the 7C-aglycone after 
supplementation with 1 mg K1.  Further support that large doses may overload the 
pathway comes from the previous isolation and definitive identification of a 10C-side 
chain length aglycone after a very large phylloquinone dose (12).  No evidence for 
this 10C-aglycone was seen on our chromatograms.  Although the preliminary 
supplementation studies shown in Table 2 using the present assay showed dose-
related increases in the urinary concentrations of both 5C- and 7C-aglycones, there 
was no consistent pattern in their relative concentrations.  The supplementation 
  18studies with K1 and members of the menaquinone series (MK-4 and MK-7) clearly 
indicate that the 5C- and 7C-aglycones are common to the major naturally occurring 
forms of vitamin K (Table 2).  Although the excretion of different forms of vitamin K 
as these two common catabolites has not been formally demonstrated before, it was to 
be expected in view of previous work that has shown that the isoprenoid side chains 
of ubiquinone-7 (33), K1 (11,37), -tocopherol (37) (41) and -tocopherol (42) are all 
shortened in the same way and excreted as equivalent metabolites.   
The proposed degradation pathway (Fig. 1) of vitamin K by successive 	- and 
-oxidation is supported by the previous unambiguous identification of 5C- and 7C-
aglycones (11), the finding of the expected 10C-side chain intermediate (12) and by 
analogy to the findings of others that the same degradation pathway operates for 
similar isoprenoid compounds (33) (42) (41).   
The increase in 5C- and 7C-aglycone excretion in response to supplementation 
with K3 is noteworthy.  The generation of MK-4 from K3 through the addition of a 
geranyl-geranyl side chain is well described (6) (7), and is the probable source of the 
increased excretion of the 5C- and 7C-aglycones following K3 supplementation.  It 
may be possible to use this metabolite assay as an index of the tissue conversion of K3 
to MK-4.  
Our ongoing work is directed at evaluating the present assay as a new marker 
of vitamin K status.  An obvious advantage over current serum measurements of 
vitamin K is that the urinary excretion reflects degradation of all K vitamins whereas 
most serum assays are only directed at the assay of a single vitamer, K1.  Thus the 
measurement of urinary excretion might be suitable as a measure of overall vitamin K 
status.  The relative contribution to total urinary excretion from K1 and MKs remains 
to be determined.  It seems likely that the majority of daily variability stems from 
  19excretion of K1 since this is by far the major dietary form, and long-chain MKs are 
thought to have a slower turnover (43).  In addition to the prerequisite for normal 
renal function, a possible disadvantage of urinary measurements as a marker of 
vitamin K stores is that metabolites of vitamin K are also excreted via the bile so that 
urinary excretion will not reflect the total elimination of vitamin K from the body.   
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  27Fig. 1. Structural formulas of phylloquinone (vitamin K1), menaquinones (vitamin 
K2), 5C-aglycone metabolite, 7C-aglycone metabolite, vitamin K γ-lactone and assay 
internal standard 
I  Phylloquinone (vitamin K1) 
II  Menaquinones (vitamin K2) 
III 2-Methyl-3-(5′-carboxy-3′-methyl-2′-pentenyl)-1,4-naphthoquinone (7C-
aglycone metabolite) 
IV 2-Methyl-3-(3′-3′-carboxymethylpropyl)-1,4-naphthoquinone (5C-aglycone 
metabolite)  
V 2-Methyl-3-(5′-carboxy-3′-hydroxy-3′-methylpentyl)-1,4-naphthoquinone 
(vitamin K -lactone) 
 
 
Fig.2. Flowchart illustrating the analytical stages involved in the determination of the 
urinary vitamin K aglycone metabolites. 
 
Fig. 3. Hydrodynamic voltammograms for the methylated urinary vitamin K 5C- (○) 
and 7C-(■) aglycone metabolites and the IS (∆).  The amounts of each compound 
injected were 16.4 fmol (4.7 pg), 15.7 fmol (4.9 pg) and 956.1 fmol (314 pg)) 
respectively.  
 
Fig. 4. Representative chromatograms obtained for calibration standards and urinary 
extracts.   
(A).  Chromatogram of a calibration standard showing the resolution of the 
methylated synthetic 5C-aglycone, 7-C aglycone, and the IS.  On-column injection 
amounts were 166fmol (47.5 pg) for the 5C-aglycone, 157fmol (49.0 pg) for the 7C-
agylcone and 960fmol (314 pg) for the IS respectively.  
(B).  Chromatogram showing measurement of aglycone metabolites at physiological 
urinary concentrations (i.e. from unsupplemented subject).  A volume of 0.5 ml urine 
was extracted and a fraction of 10/40 l of the purified extract injected.  The 
measured 5C- and 7C-aglycone concentrations were 14.76 nmol/l (4.22 g/l) and 2.82 
nmol/l (0.88 g/l) respectively.   
(C).  Chromatogram showing measurement of urinary aglycone metabolites at raised 
urinary concentrations (i.e. after oral vitamin K supplementation with 50 mg vitamin 
K1, Konakion MM).  A volume of 0.05 ml urine was extracted and a fraction of 
10/100  l of the purified extract injected.  The measured 5C- and 7C-aglycone 
concentrations were 336.36 nmol/l (96.20 g/l) and 29.32 nmol/l (9.16 g/l) 
respectively 
  28Table 1.   Assay reproducibility for the determination of the 5C- and 7C-
aglycone metabolites of vitamin K in urine  
 
5C-aglycone            7C-aglycone 
nmol/l 
 
Urine sample A 
 
Inter-assay reproducibility* (n=45) 
Mean ± SEM        14.13 ± 0.21     3.62 ± 0.06 
CV%                  9.84          12.75         
 
Urine sample B 
 
Intra-assay reproducibility   (n=10)     
Mean ± SEM         26.43 ± 0.49     5.86 ± 0.06 
CV%                   5.95           2.85 
 
 
Two separate urine collections from healthy subjects were analysed for the 5C- and 
7C-aglycone metabolites of vitamin K to assess inter-assay (A) and intra-assay 
reproducibility (B) respectively. *Inter-assay reproducibility was assessed over a 
period of 5 months. 
 
  29Table 2.  Urinary concentrations (nmol/mmol creatinine) of vitamin K metabolites (5C- and 7C-aglycones) in unsupplemented 
and vitamin K-supplemented healthy adults and neonates. 
 
UNSUPPLEMENTED SUBJECTS* 
Subject  
 
 
 
Day 1 
5C 
Day 1 
7C 
     
    
Day 2
5C 
Day 2 
7C 
nmol/mmol creatinine    nmol/mmol creatinine 
A      2.5  1.1       1.3  0.7 
B             
             
1.7 0.5 1.3 0.5
C 0.3 0.1 0.8 0.3
D      0.8  0.2       1.0  0.2 
E      0.6  0.1       0.5  <0.1 
SUPPLEMENTED SUBJECTS** 
Supplement    Dose  Pre-dose 
5C 
Pre-dose 
7C 
Post-dose 
sampling time 
Post-dose 
5C 
Post-dose 
7C 
mg  nmol/mmol creatinine  hours  nmol/mmol creatinine 
F K1  2  2.5  0.4       8  11.0  0.6 
G               
                 
                 
                 
 
 
K1  50 1.7 0.4 0-24 161.7 11.6
H MK-4 45 1.2 0.2 0-24 118.6 14.5
I MK-4 45 1.7 0.3 0-24 57.2 15.7
J MK-4 45 1.1 0.1 0-24 76.6 21.4
K  MK-7    1  0.9  0.1     24  4.2  0.6 
L  MK-7    1  1.6  0.4       4  4.8  1.4 
M K3   20  1.3  0.4       5  5.6  1.8 
N K3   20  2.5  0.5       6  17.8  5.1 
Neonate A     K1 (IM)   1  0.2  0.2       5  5.4  14.0 
Neonate B  K1  (IM)
    1  0.6  0.4     24  12.7  4.4 
Neonate C  K1  (IM)
    1  0.2  0.2     48  153.8  32.1 
 
* Unsupplemented healthy adult subjects A–E collected spot urines at 0900 on consecutive days after a 14 hr fast. **Supplemented healthy adult 
subjects F–N took the indicated vitamin K supplement orally and collected urine pre- and post-supplementation.  The pre-supplementation urines for 
subjects F–L were 24-hour collections and for subjects M–N were spot urines (early AM) immediately prior to taking the vitamin K supplement.  The 
post-supplementation urines were either spot urines collected at the time indicated (subjects F, and K–N) or entire 24-hour collections (subjects G–J).  
The neonates received 1mg of K1 intramuscularly (IM) on the first day of life.  The pre-supplementation neonatal samples represented the first void 
spot urines after delivery.  The post-supplementation neonatal samples were spot urines collected at the indicated times after IM K1.  
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